Literature DB >> 22572419

Discrepancy between myocardial perfusion and fatty acid metabolism following acute myocardial infarction for evaluating the dysfunctional viable myocardium.

Shankar K Biswas1, Masayoshi Sarai, Hiroshi Toyama, Hitoshi Hishida, Yukio Ozaki.   

Abstract

OBJECTIVE: Following acute myocardial infarction (AMI) the area of myocardial perfusion and metabolism mismatch is designated as dysfunctional viable myocardium. (123)I-beta-methyl iodophenyl pentadecanoic acid (BMIPP) is clinically very useful for evaluating myocardial fatty acid metabolism, and (99)mTc-Tetrofosmin (TF) is a widely used tracer for myocardial perfusion. This study was designed to evaluate the degree of discrepancy between BMIPP and TF at the subacute state of AMI.
METHODS: Fifty-two patients (aged 59 ± 10 years; mean 46 years) with AMI were enrolled, and all of them underwent percutaneous coronary intervention (PCI). Patients were classified according to ST-T change and PCI timing. (123)I-beta-methyl iodophenyl pentadecanoic acid and TF cardiac scintigraphy were performed on 7 ± 3.5 days of admission using a dual headed gamma camera. Perfusion and fatty acid metabolism defect were scored on a 17 segments model.
RESULTS: The mean BMIPP defect score on early and delayed images were 16.67 ± 10.19 and 16.25 ± 10.40, respectively. The mean TF defect score was 10 ± 7.69. Defect score of BMIPP was significantly higher than that of the TF (P < 0.0001; 95% CI 4.32-7.02), and there was a strong correlation between perfusion and metabolism defect score (r = 0.89, P < 0.00001). Forty-seven (90%) patients showed mismatched defect (BMIPP > TF), and 5 (10%) patients showed matched defect (BMIPP = TF). Mismatched defect score (MMDS) was significantly higher in patients with ST-segment elevation myocardial infarction (STEMI) than that of non-ST-segment elevation myocardial infarction (NSTEMI) (P < 0.041; 95% CI 0.11-5.19).
CONCLUSION: At the subacute state of AMI, most of the patients showed perfusion-metabolism mismatch, which represents the dysfunctional viable myocardium, and patients with STEMI showed higher mismatch.
Copyright © 2012 Cardiological Society of India. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22572419      PMCID: PMC3860991          DOI: 10.1016/S0019-4832(12)60005-4

Source DB:  PubMed          Journal:  Indian Heart J        ISSN: 0019-4832


  33 in total

1.  Integrated analysis of myocardial blush and ST-segment elevation recovery after successful primary angioplasty: Real-time grading of microvascular reperfusion and prediction of early and late recovery of left ventricular function.

Authors:  Arnaldo Poli; Raffaela Fetiveau; Pietro Vandoni; Gianfranco del Rosso; Maurizio D'Urbano; Giovanni Seveso; Francesco Cafiero; Stefano De Servi
Journal:  Circulation       Date:  2002-07-16       Impact factor: 29.690

Review 2.  Lipid metabolism in the heart--contribution of BMIPP to the diseased heart.

Authors:  R Nohara
Journal:  Ann Nucl Med       Date:  2001-10       Impact factor: 2.668

3.  Relation between serum-free-fatty acids and arrhythmias and death after acute myocardial infarction.

Authors:  M F Oliver; V A Kurien; T W Greenwood
Journal:  Lancet       Date:  1968-04-06       Impact factor: 79.321

4.  Effects of excess free fatty acids on mechanical and metabolic function in normal and ischemic myocardium in swine.

Authors:  A J Liedtke; S Nellis; J R Neely
Journal:  Circ Res       Date:  1978-10       Impact factor: 17.367

5.  ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction--summary article: a report of the American College of Cardiology/American Heart Association task force on practice guidelines (Committee on the Management of Patients With Unstable Angina).

Authors:  Eugene Braunwald; Elliott M Antman; John W Beasley; Robert M Califf; Melvin D Cheitlin; Judith S Hochman; Robert H Jones; Dean Kereiakes; Joel Kupersmith; Thomas N Levin; Carl J Pepine; John W Schaeffer; Earl E Smith; David E Steward; Pierre Theroux; Raymond J Gibbons; Joseph S Alpert; David P Faxon; Valentin Fuster; Gabriel Gregoratos; Loren F Hiratzka; Alice K Jacobs; Sidney C Smith
Journal:  J Am Coll Cardiol       Date:  2002-10-02       Impact factor: 24.094

6.  Prognostic value of impaired myocardial fatty acid uptake in patients with acute myocardial infarction.

Authors:  T Nakata; T Kobayashi; N Tamaki; H Kobayashi; T Wakabayashi; S Shimoshige; K Oh-Hori; K Hamabe; K Hirasawa; T Matsuki; T Shogase; M Furudate; K Shimamoto
Journal:  Nucl Med Commun       Date:  2000-10       Impact factor: 1.690

7.  Dynamic changes in cardiac fatty acid metabolism in the stunned human myocardium.

Authors:  K Ito; H Sugihara; T Kawasaki; S Katoh; A Azuma; M Nakagawa
Journal:  Ann Nucl Med       Date:  2001-08       Impact factor: 2.668

8.  ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction--executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to revise the 1999 guidelines for the management of patients with acute myocardial infarction).

Authors:  Elliott M Antman; Daniel T Anbe; Paul Wayne Armstrong; Eric R Bates; Lee A Green; Mary Hand; Judith S Hochman; Harlan M Krumholz; Frederick G Kushner; Gervasio A Lamas; Charles J Mullany; Joseph P Ornato; David L Pearle; Michael A Sloan; Sidney C Smith
Journal:  J Am Coll Cardiol       Date:  2004-08-04       Impact factor: 24.094

Review 9.  Early discharge after acute myocardial infarction.

Authors:  D B Pryor; M C Hindman; G S Wagner; R M Califf; M K Rhoads; R A Rosati
Journal:  Ann Intern Med       Date:  1983-10       Impact factor: 25.391

10.  Serial changes in BMIPP uptake in relation to thallium uptake in the rat myocardium after ischaemia.

Authors:  Kazuyuki Noriyasu; Megumi Mabuchi; Yuji Kuge; Koichi Morita; Takahiro Tsukamoto; Tetsuro Kohya; Akira Kitabatake; Nagara Tamaki
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-09-03       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.